Sara M. Tolaney, MD, MPH

Sara M Tolaney, MD is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.

Articles

Trastuzumab Deruxtecan (T-DXd) + Pertuzumab (P) vs Taxane + Trastuzumab + Pertuzumab (THP) for First-Line (1L) Treatment of Patients With Human Epidermal Growth Factor Receptor 2–Positive (HER2+) Advanced/Metastatic Breast Cancer (a/mBC): Interim Results From DESTINY-Breast09

June 17th 2025

Sara Tolaney, MD, MPH, presents results from the phase 3 DESTINY-Breast09 study showing that trastuzumab deruxtecan plus pertuzumab improved progression-free survival vs taxane, trastuzumab and pertuzumab (THP) as a first-line treatment in patients with HER2 positive metastatic breast cancer.

Dr Tolaney on the Clinical Implications of First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 5th 2025

Sara M. Tolaney, MD, MPH, details the clinical implications for first-line T-DXd/pertuzumab for the treatment of patients with HER2-positive breast cancer.

Dr Tolaney on the PFS Benefit With First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 2nd 2025

Sara M. Tolaney, MD, MPH, shares interim efficacy results from the DESTINY-Breast09 study of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

Dr Tolaney on the Optimal Timing of ESR1 Testing in HR+ Breast Cancer

April 17th 2025

Sara M. Tolaney, MD, MPH, discusses the ideal time for patients with HR-positive breast cancer to undergo genetic testing for ESR1 mutations.

Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer

March 8th 2025

Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.

Dr Tolaney on the Development of TROP2-Directed ADCs in Breast Cancer

September 3rd 2024

Sara M. Tolaney, MD, MPH, discusses the utility of TROP2-directed antibody-drug conjugates in the treatment of patients with breast cancer.

Dr Tolaney on the Sequential Use of ADCs in Breast Cancer

August 30th 2024

Sara M. Tolaney, MD, MPH, discusses the sequential use of antibody-drug conjugates in the treatment of patients with breast cancer.

Dr Tolaney on Standard Frontline Treatment Approaches in HER2+ Breast Cancer

August 29th 2024

Sara M. Tolaney, MD, MPH, discusses standard-of-care frontline treatment approaches for patients with HER2-positive breast cancer.

Dr Tolaney on Frontline Treatment Approaches in HER2+ Breast Cancer

August 20th 2024

Sara M. Tolaney, MD, MPH, discusses standard frontline treatment approaches for patients with HER2-positive breast cancer.

Dr Tolaney on Data With Checkpoint Inhibitor Combinations in Metastatic TNBC

August 7th 2024

Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.

Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast Cancer

August 6th 2024

Sara M. Tolaney, MD, MPH discusses ongoing clinical trials investigating the addition of HER2-directed therapies to existing treatment regimens for HER2-positive breast cancer.

Dr Tolaney on the Development of Mutation-Selective PI3K Inhibitors in Breast Cancer

July 24th 2024

Sara M. Tolaney, MD, MPH, discusses the ongoing development of mutation-selective PI3K inhibitors in PI3K-mutant metastatic breast cancer.

Dr Tolaney on the Potential Role for Biomarkers in Early-Stage HER2+ Breast Cancer

July 24th 2024

Sara M. Tolaney, MD, MPH, discusses the potential role for biomarkers in guiding treatment decisions in early-stage HER2-positive breast cancer.

A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2- Positive Metastatic Breast Cancer With Brain Metastases (BMs) from DESTINY-Breast01, -02, and -03

April 2nd 2024

Sara Tolaney, MD, MPH, presents an exploratory pooled analysis of efficacy and safety data of trastuzumab deruxtecan vs comparator in patients with HER2-positive metastatic breast cancer and brain metastases from DESTINY-Breast01, -02, and -03.

Dr Tolaney on the Real-World Efficacy of T-DXd in HER2+ or HER2-Low Breast Cancer

December 15th 2023

Sara M. Tolaney, MD, MPH, discusses the real-world efficacy of fam-trastuzumab deruxtecan in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course.

Dr Tolaney on Sequencing Available ADCs in Breast Cancer

December 8th 2023

Sara M. Tolaney, MD, MPH, discusses the current utilization of antibody-drug conjugates in patients with hormone receptor-positive, HER2-negative breast cancer, highlighting the question of sequencing among available agents.

Dr Tolaney on Final OS Data From the TROPiCS-02 Trial in HR+/HER2- Breast Cancer

June 7th 2023

Sara M. Tolaney, MD, MPH, discusses key data from a final overall survival analysis of the phase 3 TROPiCS-02 trial in hormone receptor–positive, HER2-negative breast cancer.

Closing Remarks on Treating Patients with HR+ Breast Cancer

February 13th 2023

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.

Treatment after Progression on CDK4/6 Inhibitors

February 6th 2023

A detailed look at treatment options for patients with metastatic HR+ breast cancer who have progressed on CDK4/6 inhibitors.

The Role of Surgery in Breast Cancer

February 6th 2023

Experts in oncology consider when surgery is appropriate for patients with breast cancer.